FFAR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Phenyl Propionic Acid (SCHEMBL3419)	0.91	13/20
SCHEMBL5455	0.71	12/20
SCHEMBL5859	0.64	12/20
SCHEMBL5860	0.67	11/20
Cetraxate (SCHEMBL19437)	0.46	11/20
SCHEMBL6614	0.50	10/20
SCHEMBL6615	0.50	9/20
SCHEMBL8242	0.50	9/20
SCHEMBL14245	0.49	9/20
SCHEMBL5948	0.45	9/20
SCHEMBL5950	0.43	9/20
Hydroxyphenyl Propionic Acid (SCHEMBL35486)	0.68	8/20
SCHEMBL7260	0.48	8/20
SCHEMBL5636	0.47	8/20
SCHEMBL40250	0.57	7/20
SCHEMBL5861	0.56	7/20
Englitazone (SCHEMBL37697)	0.47	7/20
SCHEMBL14243	0.44	7/20
Phenylbutanoic Acid (SCHEMBL1716)	0.69	6/20
SCHEMBL6182	0.69	6/20

Clinical trials — most relevant to FFAR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Fat, Inflammation and Insulin Resistance	PHASE4	COMPLETED
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes	PHASE4	COMPLETED
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
Omega 3 Supplementation in Fatty Liver	PHASE3	COMPLETED
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome	PHASE2/PHASE3	COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
Colonic Propionate, Appetite, and Weight Loss	nan	COMPLETED
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis	nan	WITHDRAWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Molecular Pathways Related to Short-term Fasting Response	nan	COMPLETED
FFA Hypertension and Inflammation in Lean and Obese Subjects	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6	nan	COMPLETED
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus	nan	COMPLETED
The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity	nan	COMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients	nan	COMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion	nan	COMPLETED
Growth Hormone Signaling in Vivo in Humans	nan	COMPLETED
Regional Fat Depots and Insulin Resistance	nan	COMPLETED
Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis	nan	COMPLETED
Gut Microbiota and Modulation of Liver Damage in NAFLD	nan	COMPLETED
The Impact of Rosiglitazone on Regression of Atherosclerosis	nan	SUSPENDED

Related proteins — ESM-2 sequence neighbours (a FFAR1 binder may also engage these)

Protein	Name	Similarity
Q76JU9	—	0.998	Q76JU9 →
Q76JV1	—	0.998	Q76JV1 →
Q76JU8	—	0.992	Q76JU8 →
Q8K3T4	—	0.989	Q8K3T4 →
Q920E0	—	0.979	Q920E0 →
A0A6I8PUB9	—	0.976	A0A6I8PUB9 →
O88634	—	0.973	O88634 →
F2RL3	Proteinase-activated receptor 4	0.972	landscape →
P2RY11	P2Y purinoceptor 11	0.971	landscape →
Q9JL21	—	0.971	Q9JL21 →
O00155	—	0.970	O00155 →
P0C5I1	—	0.969	P0C5I1 →
FFAR3	Free fatty acid receptor 3	0.969	landscape →
RXFP4	Relaxin-3 receptor 2	0.969	landscape →
O00270	—	0.968	O00270 →
LPAR5	Lysophosphatidic acid receptor 5	0.965	landscape →
CCR10	C-C chemokine receptor type 10	0.965	landscape →
Q3ZC80	—	0.964	Q3ZC80 →
O15529	—	0.962	O15529 →
Q924U0	—	0.961	Q924U0 →
Q9JJL9	—	0.961	Q9JJL9 →
GPBAR1	G-protein coupled bile acid receptor 1	0.959	landscape →
Q862A8	—	0.958	Q862A8 →
Q99678	—	0.957	Q99678 →
Q96P69	—	0.957	Q96P69 →
Q149R9	—	0.957	Q149R9 →
OXER1	Oxoeicosanoid receptor 1	0.955	landscape →
C5AR2	C5a anaphylatoxin chemotactic receptor 2	0.955	landscape →
Q80SS6	—	0.955	Q80SS6 →
Q862A9	—	0.954	Q862A9 →